Get the Stockscreener App
4.76
5.93%
-0.30
After Hours:
4.89
0.13
+2.73%
Ars Pharmaceuticals Inc stock is traded at $4.76, with a volume of 2.57M.
It is down -5.93% in the last 24 hours and down -20.00% over the past month.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
See More
Previous Close:
$5.06
Open:
$5.13
24h Volume:
2.57M
Relative Volume:
1.31
Market Cap:
$473.37M
Revenue:
$98.99M
Net Income/Loss:
$-197.98M
P/E Ratio:
-2.378
EPS:
-2.0017
Net Cash Flow:
$-175.32M
1W Performance:
-15.30%
1M Performance:
-20.00%
6M Performance:
-43.20%
1Y Performance:
-53.10%
1-Day Range:
$4.73
$5.19
1-Week Range:
$4.73
$5.535
52-Week Range:
$4.73
$13.15
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Name
Ars Pharmaceuticals Inc
Sector
Industry
Phone
858-771-9307
Address
11682 EL CAMINO REAL, SUITE 300, SAN DIEGO
Compare SPRY vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
4.76 | 503.20M | 98.99M | -197.98M | -175.32M | -2.0017 |
VRTX
Vertex Pharmaceuticals Inc
|
515.44 | 130.42B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
781.49 | 81.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.39 | 61.56B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
143.97 | 54.54B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.77 | 43.59B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-26 | Initiated | Northland Capital | Outperform |
| Nov-04-25 | Resumed | Roth Capital | Buy |
| Sep-04-25 | Initiated | Roth Capital | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-10-25 | Initiated | Oppenheimer | Outperform |
| Aug-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-12-24 | Reiterated | Leerink Partners | Outperform |
| Jul-25-24 | Initiated | Raymond James | Outperform |
| Mar-05-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-20-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Sep-20-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-31-23 | Initiated | Wedbush | Outperform |
| Jan-03-23 | Initiated | William Blair | Outperform |
| Dec-13-22 | Initiated | SVB Leerink | Outperform |
View All
Ars Pharmaceuticals Inc Stock (SPRY) Latest News
SPRY SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Robbins LLP Reminds Investors of the Securities Fraud Class - GlobeNewswire
Richard Lowenthal to sell 35,000 ARS Pharma (SPRY) shares - Stock Titan
ARS Pharmaceuticals (SPRY) officer sold $250K in stock and plans more - Stock Titan
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit - Morningstar
Bragar Eagel & Squire, P.C. Reminds ARS Pharmaceuticals - GlobeNewswire
ARS Pharma at Cantor Global Healthcare: provider push lifts neffy By Investing.com - Investing.com Canada
ARS Pharma at Cantor Global Healthcare: provider push lifts neffy - Investing.com India
SueWallSt Reminds ARS Pharmaceuticals Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026SPRY - PR Newswire
רוזן, יועץ למשקיעים מהימן, קורא למשקיעי ARS Pharmaceuticals, Inc. לשכור ייצוג משפטי לקראת מועד אחרון חשוב בתביעה הייצוגית בניירות הערך – SPRY - GlobeNewswire Inc.
SPRY EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ARS Pha - The National Law Review
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ARS - GlobeNewswire
SPRY Stock Tanks Over 23% After-Hours — ARS Pharmaceuticals Reports No New Major Insurance Wins For Neffy - Stocktwits
SPRY Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in ARS Pharmaceuticals Securities LawsuitContact Levi & Korsinsky - PR Newswire
Kaplan Fox Deadline Alert: ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors Have Until October 5, 2026 to Seek a Lead Plaintiff Role - newmediawire.com
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
symbol__ Stock Quote Price and Forecast - CNN
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm - lincolnjournal.com
SPRY Should I Buy - Intellectia AI
ROSEN, A TOP RANKED LAW FIRM, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionSPRY - ACCESS Newswire
Another ARS Pharma (NASDAQ: SPRY) insider stock sale is coming, with the size now disclosed - Stock Titan
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire
Kaplan Fox Continues to Remind ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors of the Lead Plaintiff Deadline on October 5, 2026 - NewMediaWire
ARS Pharmaceuticals (SPRY) insider lines up Sept. 3 stock sale after August trades - Stock Titan
Faruqi & Faruqi, LLP Urges ARS Pharmaceuticals (SPRY) Investors t - The National Law Review
SPRY UPCOMING DEADLINE: SueWallSt Alerts ARS Pharmaceuticals Inc. Stockholders of Securities Class ActionContact the Firm - Morningstar
Chief commercial officer at ARS Pharma (SPRY) gets 1.0M stock options - Stock Titan
Insider at ARS Pharmaceuticals (NASDAQ: SPRY) plans another stock sale - Stock Titan
ARS Stock Drop: Robbins LLP Reminds Investors They May Be Eligible to Lead the Class Action Against ARS Pharmaceuticals Inc. - newsfilecorp.com
SPRY Shareholder Alert: ARS Pharmaceuticals Inc. Securities Class Action LawsuitInvestors Should Contact Levi & Korsinsky - PR Newswire
Kaplan Fox Continues to Alert Investors of a Securities Class Act - The National Law Review
Kaplan Fox Continues to Alert Investors of a Securities Class Action Deadline on October 5, 2026 Against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) - NewMediaWire
Repeat insider selling at ARS Pharma (SPRY) now includes a planned early-September trade - Stock Titan
Acurx Pharmaceuticals, Inc. SEC Filing (Sep 1, 2026) - Stock Titan
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
SPRY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SPRY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
ROSEN, REGARDED INVESTOR COUNSEL, Encourages ARS - GlobeNewswire
ARS Pharma (NASDAQ: SPRY) insider lines up new sale after August stock disposals - Stock Titan
SPRY Shareholder Alert: ARS Pharmaceuticals Inc. Securities - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals - GlobeNewswire
SPRY CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharma - The National Law Review
ROSEN, NATIONAL TRIAL LAWYERS, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel ... - Herald and News
Kaplan Fox Continues to Alert Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to a Class Action Deadline on October 5, 2026 - The Globe and Mail
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming DeadlinesSPRY - PR Newswire
ARS PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. - globenewswire.com
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. LawsuitSPRY - Morningstar
Kaplan Fox Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Inv - The National Law Review
Levi & Korsinsky Reminds ARS Pharmaceuticals Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026SPRY - PR Newswire
ROSEN, NATIONAL TRIAL COUNSEL, Encourages ARS - GlobeNewswire
SPRY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Ars Pharmaceuticals Inc Stock (SPRY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
1.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):